(Part 3 of 6) Substance Use Disorder: Initiating Buprenorphine in the Fentanyl Era and Other Treatment Considerations in Patients With Opioid Use Disorder and HIV

Presenter

Leah J. Leisch, MD
The University of Alabama at Birmingham

Moderator

Sandra A. Springer, MD
Yale University

October 5, 2023

11:30 AM - 12:45 PM PT

Overview

Assessment of Needs

Substance use disorder, including the misuse of opioids, may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of opioid use disorder and understand the current treatment options and challenges.

Drug Enforcement Agency certificate holders are now required to complete 8 hours of training on opioids, substance use disorders (SUDs), and pain management. The IAS–USA is excited to support you in meeting these new requirements with a free, 6-part webinar series comprising 8 hours of training to help you provide the best possible care for your HIV patients! The third webinar in the series, presented by Leah J. Leisch, and moderated by Sandra Springer, MD, focuses on opioid use disorder in patients with HIV.

Learning Objectives

 On completion of this activity, learners will be able to: 

  • Discuss the 3 US Food and Drug Administration-approved medications for opioid use disorder and how they relate to HIV care
  • Utilize standard induction protocols for buprenorphine in patients with HIV and opioid use disorder
  • Practice alternate strategies of initiation of buprenorphine in patients with HIV, opioid use disorder, and significant fentanyl use

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Thursday, October 5, 2023, 12:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Leisch reported no relevant financial relationships with ineligible companies. (Updated August 22, 2023)

Moderator

Dr Springer reported receiving consulting fees from Alkermes, Inc, and receiving in-kind study drug donations from Alkermes, Inc, and Indivior, Inc. (Updated August 10, 2023)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated August 15, 2023)

Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated August 15, 2023)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ 

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-23-537-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

BRONZE SUPPORTERS

Janssen Therapeutics
Theratechnologies Inc.

 

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.